efruxifermin

Efruxifermin is an investigational bivalent Fc-FGF21 fusion protein engineered to mimic the biological activity of native fibroblast growth factor 21. It is designed to reverse fibrosis, reduce liver fat and inflammation, increase insulin sensitivity, and improve lipoproteins in patients with nonalcoholic steatohepatitis and related metabolic disorders. Efruxifermin is administered as a once-weekly subcutaneous injection and has demonstrated efficacy in improving liver fibrosis and resolving NASH in clinical trials[2][4][6].

Other names

Immunoglobulin g (synthetic human constant domain fc fragment) fusion protein with fibroblast growth factor 21 (98-arginine,171-glycine,180-glutamic acid) (human mutant clone amg876)Immunoglobulin g1 (human .gamma.1-chain c-region c-terminal fragment) fusion protein with peptide linker (ggggs)3 fusion protein with fibroblast growth factor 21 (98-arginine,171-glycine,180-glutamic acid) (human), dimer